BlueBee has established a data center in mainland China in order to aid expansion of global coverage for its genomics data platform.

The global bioinformatics solutions provider has extended data operations in compliance with The Chinese Ministry of Health and Technology.

This strategic move will serve existing and new BlueBee customers who integrate bioinformatic data solutions with their analytical instruments, omics assay technology, or high-throughput laboratory services, according to a statement.

BlueBee states it expects this investment will result in mutual growth for BlueBee and its partner clients due to immediate demand from its existing customer base and projected growth of the Chinese genomics market.

Many geographical regions require that personal health information (PHI), which includes genomics data, and personal identification information (PII), remain within the regional border, the company states. Because of this, BlueBee continues to build its global infrastructure for omics-related health data.

Currently the BlueBee Genomics Platform is enabled in more than 50 countries, in virtually any defined ‘region' on demand.

Geographical regions that are enabled to date include: in Europe: France, Belgium, The Netherlands, England, Germany, Italy, Denmark, Finland; in the Americas: USA, Canada, Brazil; and in Asia Pacific: China, Australia, Japan, South Korea, Hong Kong, Singapore, Taiwan.

A single BlueBee data solution can span any number of discrete geographies while still achieving regional data residency and compliance, the company states.

This includes a single window orchestration layer, which presents a global, centralised view of all data operations on the BlueBee platform. As such, distributed operations of a global assay or service provider can be accessed in real time from virtually anywhere on the globe. the company states.

BlueBee CEO Hans Cobben says, “We were drawn to setting up our mainland China data center to meet the demands of partner clients.

“Serving the global community remains at the helm of our mandate, and we built a technology solution that is literally capable of serving the Chinese population which represents a fifth of the world's population, on demand, while meeting data compliance requirements.

“We are now poised with a pipeline of prospects looking to launch commercial molecular assay or service offerings in China with an integrated data analytics solution,” Cobben adds.